Radiotherapy: Long-term effects on gastrointestinal function

Current Opinion in Supportive and Palliative Care

Volumn 2, Issue 1, 2008, Pages 40-44

  Yeoh, Eric ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Anorectal dysfunction; Late (gastrointestinal) toxicity; Radiation mucositis; Radiation proctitis; Radiation therapy

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE;

BLOOD; GASTROENTERITIS; GASTROINTESTINAL TRACT; HUMAN; NEOPLASM; QUALITY OF LIFE; RADIATION EXPOSURE; RADIOTHERAPY; REVIEW; RISK FACTOR; TIME;

CYCLOOXYGENASE 2; CYTOKINES; GASTROENTERITIS; GASTROINTESTINAL TRACT; HUMANS; NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; RISK FACTORS; TIME FACTORS;

EID: 56149120878     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3282f4451f     Document Type: Review

References (33)

1. Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut 2005; 54:1051-1054.
2. Brush J, Scott L, Phillips T, et al. Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol 2007; 17:121 -130. Current knowledge of the molecular mechanisms of late effects of radiation on normal tissues are reviewed, including an overview of their role in the long-term effects on the gut based on animal and human data.
3. Feng M, Hanlon AL, PisanskyTM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68:1417-1423.
4. Jung C, Cookson MS, Chang SS, et al. Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int 2006; 99:529-533.
5. Ishikawa H, Tsuji H, Kamada T, et al. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66:1084-1091.
6. Yeoh EE, Holloway SH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomised trial. Int J Radiat Oncol Biol Phys 2006; 66:1072-1083. One of a few studies with prospective longitudinal toxicity data based on patient and physician questionnaires including the effect on activities of daily living up to 5 years after radiotherapy of early prostate cancer. The toxicity data are pertinent with the current interest in hypofractionated radiotherapy for prostate cancer, particularly in the design of escalated hypofractionated dose schedules.
7. Goldner G, Tomicek B, Becker G, et al. Proctitis after external beam radiotherapy for prostate cancer classified by Vienna rectoscopy score and correlated with EORT/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 2007; 67:78-83. Prospective, longitudinal data from this multicentre study of external beam radiotherapy indicate scoring of rectal mucosal changes by sigmoidoscopy is significantly more sensitive than symptom scoring using the physician-based European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group questionnaires.
8. Di Matteo A, Botten R, Holloway R, et al. Anorectal dysfunction persists and adversely impacts daily activities 5 years after radiation treatment of prostate carcinoma [abstract]. Gastroenterology 2006; 130 (Suppl 2):A726.
9. Konishi T, Watanabe T, Nagawa H. Treatment of local ischaemia: another promising approach for gastrointestinal complications of pelvic radiotherapy [letter]. Gut 2006; 55:1209.
10. Okunieff P, Cornelison J, Mister M, et al. Mechanism and modification of gastrointestinal soft tissue response to radiation: role of growth factors. Int J Radiat Oncol Biol Phys 2005; 62:273-278.
11. kB and cyclo-oxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 2005; 63:1295-1303.
12. Keskek M, Gocmen E, Kilic M, et al. Increased expression of cyclooxygenase2 (COX2) in radiation-induced small bowel injury in rats. J Surg Res 2006; 135:76-84. One of the first studies to implicate the COX-2 pathway in radiation bowel disease. The data suggest its role in amplifying rather than initiating radiation injury. COX-2 inhibators such as Rofecoxib would therefore be potentially useful in ameliorating radiation bowel damage.
13. Bourgier C, Haydont V, Milliat F, et al. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut 2005; 54:336-343.
14. Jazwinski A, Palazzo J, Kastenberg D, et al. Capsule endoscopy diagnosis of radiation enteritis previously thought to be celiac sprue. Endoscopy 2007. [Epub ahead of print]. www.thieme-connect.de/ejournals/ abstract/endoscopy/ doi/10.1055/s-2006-944715
15. Wilson SA, Rex DK. Endoscopic treatment of chronic radiation proctopathy Curr Opin Gastroenterol 2006; 22:536-540. Review of the development of endoscopic treatments for rectal bleeding- associated chronic radiation proctitis following pelvic radiation therapy. Argon plasma coagulation therapy emerges as the treatment of choice based on available published data.
16. Pasha SF, Harrison ME, Leighton JA. Obscure GI bleeding secondary to radiation enteritis diagnosed and successfully treated with retrograde double- balloon enteroscopy. Gastrointest Endosc 2007; 65:552-554.
17. Venerito M, Monkemuller K, Rickes S, Malfertheiner P. Education and imaging gastrointestinal: radiation proctitis [letter]. Gastroenterol Hepatol 2007; 22:761. Brief but excellent article that not only provides a comprehensive summary of the pathology underlying radiation bowel damage, but good quality endoscopic images of the mucosal telengectasia(or neovascular mucosal lesions) responsible for rectal bleeding are also included.
18. Postgate A, Saunders B, Tjandra J, Vargo J. Argon plasma coagulation in chronic radiation proctitis. Endoscopy 2007; 39:361 -365. eview of the rationale, effectiveness, limitations and complications of argon plasma coagulation, currently the treatment of choice for haemorrhagic radiation proctitis.
19. Konishi T, Watanabe T, Kitayama J, et al. Endoscopic and histopathologic findings after formalin application for hemorrhage caused by chronic radiation- induced proctitis. Gastrointest Endosc 2005; 61:161 -164.
20. Stern DR, Steinhagen RM. Anorectal cancer following topical formalin application for haemorrhagic radiation proctitis. Colorectal Dis 2007; 9:275-278.
21. Botten R, Di Matteo A, Tam W, et al. Anorectal dysfunction persists despite APC and formalin for chronic radiation proctitis [abstract]. J Gastroenterol epatol 2005; 20 (Suppl):A92.
22. Craanen ME,van TriestB,VerheijenRHM,MulderCJJ.Thalidomidein refractory haemorrhagic radiation induced proctitis [letter]. Gut 2006; 55:1371-1372.
23. Marshall GT, Thirlby RC, Bredfeldt JE, Hampson NB. Treatment of gastrointestinal radiation injury with hyperbaric oxygen. Undersen Hyperb Med 007; 34:35-42. eport based on the largest clinical series using hyperbaric oxygen in the treatment of gastrointestinal radiation injury. Although a nonrandomized study, the rationale of the tment is discussed the interim results of a randomized, double-blind, placebo-controlled trial are provided.
24. Raman RR. Ten percentage formalin retention enemas for haemorrhagic radiation proctitis: a preliminary report. Dis Colon Rectum 2007; 50:1032-1039.
25. Haas EM, Bailey HR, Farragher I. Application of 10 percentage formalin for the treatment of radiation-induced haemorrhagic proctitis. Dis Colon Rectum 2006; 50:213-217. A nonrandomized study reporting comparable efficacy and toxicity of a novel outpatient-based treatment of haemorrhagic radiation proctitis using 10% formalin on a cotton-tip applicator to the conventional 4% formalin topical applications. Patient demand for this approach is likely to increase as no anaesthesia or bowel preparation is required.
26. Cesaretti JA, Stock RG, Atencio DP, et al. A genetically determined dosevolume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007; 68:1410-1416. A predictive assay for toxicity (rectal bleeding) after prostate brachytherapy based on variants of the ataxia telangiectasia gene is suggested, which also serves as a basis for the individualization of radiation dose prescriptions.
27. Di Matteo A, Botten R, Tamblyn D, et al. Micronutrients may reduce GI morbidity following radiation therapy for prostate carcinoma [abstract]. Gas- troenterology 2005; 128 (Suppl):A265.
28. Su AW, Jani AB. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol 2007; 30:215-219.
29. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006; 24:5298-5304.
30. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy. Cancer 2007; 109:1506-1512.
31. Peters CA, Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2006; 66:424-429.
32. Heemsbergen WD, Peeters STH, Koper PCM, et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 2006; 66:3-10. The article highlights the importance of controlling acute gastrointestinal toxicity in order to reduce the impact of long-term gastrointestinal effects of radiotherapy for prostate cancer.
33. Haider N, O'Sullivan C, Corbally MT, Fitzgerald RJ. Abdominopelvic mesh compartmentalization reducesthe complications of radiotherapy in children: a preliminary report. Eur J Pediatr Surg 2006; 16:348-351.